Insilico Medicine

Boston, Massachusetts, USA (with significant operations in Hong Kong and New York) All United States companies → — Founded 2014

AI Research Lab Biotech / Drug Discovery

Oncology

Drug Discovery & Research

Public (listed on Hong Kong Stock Exchange, SEHK: 3696)

Website Claim this company

Products

Insilico Medicine

Drug Discovery & Research

Insilico Medicine uses generative AI and automation to accelerate drug discovery and development, aiming to reduce time and cost for bringing life-saving medications to patients.

Contact for pricing

See all 1 product →

About Insilico Medicine

Insilico Medicine is a pioneering clinical-stage biotechnology company that leverages generative artificial intelligence (AI) to transform and accelerate the drug discovery and development process. The company’s proprietary end-to-end Pharma.AI platform integrates advanced AI algorithms across biology, chemistry, and clinical trial analysis. This platform comprises key modules such as PandaOmics for novel target discovery and disease hypothesis generation, and Chemistry42 for designing novel molecular structures with desired properties, often significantly reducing the time and cost compared to traditional methods.

For physicians, Insilico Medicine’s approach means a faster pipeline for identifying and developing potential therapeutic agents for a wide range of challenging diseases. By combining genomics, big data analysis, and deep learning, Insilico aims to pinpoint previously unaddressed disease targets and rapidly generate drug candidates. The company has successfully advanced several programs into clinical trials, including a lead anti-fibrotic drug candidate for Idiopathic Pulmonary Fibrosis (IPF) that is in Phase II trials, representing the first generative AI-designed drug for an AI-discovered target to reach this stage.

Insilico Medicine is committed to extending healthy longevity by focusing on diseases closely linked to aging, such as fibrosis, oncology, immunology, and central nervous system disorders. Their AI-driven platforms are designed to not only discover traditional drugs but also to identify dual-purpose targets that address both specific diseases and underlying aging processes, ultimately striving to bring innovative and life-saving medications to patients more rapidly.

What Physicians Need to Know

AI-Driven Drug Discovery & Development

Insilico Medicine specializes in end-to-end generative AI for drug discovery, significantly accelerating the process from target identification to preclinical candidate nomination and clinical trial prediction. Their Pharma.AI platform integrates biology, chemistry, and clinical development.

Key Therapeutic Areas

Their pipeline focuses on developing novel therapies for challenging conditions including cancer, fibrosis (with a lead drug for Idiopathic Pulmonary Fibrosis in Phase II trials), immunity, central nervous system (CNS) disorders, and aging-related diseases.

Target Identification (PandaOmics)

PandaOmics, their AI-powered platform, rapidly identifies and prioritizes novel therapeutic targets by analyzing vast multi-omics datasets (genomic, transcriptomic, proteomic) and integrating information from publications and clinical trials.

Generative Chemistry (Chemistry42)

Chemistry42 is Insilico's generative chemistry engine that designs novel small molecules with desired properties from scratch, utilizing deep learning, generative adversarial networks (GANs), and transformer models.

Clinical Trial Prediction (inClinico)

The inClinico platform leverages AI to forecast clinical trial outcomes, aiming to maximize the chances of successful clinical development.

Speed & Cost Efficiency

Insilico has demonstrated a dramatic reduction in drug discovery timelines and costs, achieving preclinical candidate nomination in 12-18 months (compared to 3-6 years traditionally) and at approximately 10% of conventional expenses.

Validated Clinical Progress

A significant differentiator is having the first generative AI-discovered and designed drug (INS018_055 for idiopathic pulmonary fibrosis) advance into Phase II human clinical trials, validating their end-to-end AI platform.

Advanced AI/ML Technologies

Their technology stack includes deep learning, generative adversarial networks (GANs), reinforcement learning, transformer models, large language models (LLMs), and even explores quantum machine learning (QML) for molecular design and prediction.

AI Assistant for Research (DORA)

Insilico offers DORA, an AI assistant designed to help researchers, including physicians, in drafting academic papers, case studies, grants, and patent applications, aiming to unlock and disseminate medical knowledge more efficiently.

Secure Localized Analysis (PandaOmics Box)

For enhanced data privacy and security, Insilico provides the PandaOmics Box, an offline server solution for localized, secure AI-driven analysis of sensitive data.

Physician Tip

For physicians, Insilico Medicine's advancements mean the potential for faster access to novel, effective therapies for diseases with high unmet needs, such as idiopathic pulmonary fibrosis and various cancers. The validation of their AI-discovered and designed drug in clinical trials demonstrates a tangible shift in drug development, promising more targeted and efficient treatments. Furthermore, tools like DORA can empower physicians to contribute more readily to medical research by streamlining the drafting of papers and grants, fostering knowledge sharing and potentially influencing future clinical practice. The focus on healthy longevity also aligns with a growing emphasis on preventive and long-term care.

Insilico Medicine's Pharma.AI platform is primarily designed for pharmaceutical and biotech R&D teams and partners. They utilize cloud infrastructure like Amazon SageMaker and NVIDIA Tensor Core GPUs for their AI models. They also collaborate with major pharmaceutical companies like Eli Lilly. While their core platforms are not direct clinical integrations for hospitals, the PandaOmics Box offers a secure, localized analysis option for sensitive data, which could be relevant for research-focused clinical settings. Their Nach01 foundation model is also being demonstrated on Microsoft Discovery for AI-accelerated R&D, indicating potential for broader platform integrations in research workflows.

At a glance

Founded 2014

HQ Boston, Massachusetts, USA (with significant operations in Hong Kong and New York) · United States

CEO Alex Zhavoronkov, PhD

Funding Public (listed on Hong Kong Stock Exchange, SEHK: 3696)

Products 1

Visit site

Products by Insilico Medicine

1 product in the directory

Insilico Medicine

Drug Discovery & Research

Insilico Medicine uses generative AI and automation to accelerate drug discovery and development, aiming to reduce time and cost for bringing life-saving medications to patients.

Contact for pricing

What the Web Says

Insilico Medicine is an AI-driven drug discovery company that utilizes its Pharma.AI platform (PandaOmics, Chemistry42, and inClinico) to accelerate the drug development pipeline from target identification to preclinical candidate nomination and clinical trial prediction. The company has successfully advanced AI-discovered and designed molecules into clinical trials, significantly reducing the time and cost associated with traditional drug discovery methods. While its product offerings are highly praised for innovation and efficiency, employee reviews indicate significant concerns regarding management, work-life balance, and company culture.

Overall: Mixed

Strengths

Accelerates drug discovery timelines significantly, reducing years to months.
End-to-end AI platform covering target identification, molecule generation, and clinical prediction.
Successfully advanced AI-discovered and designed drugs into clinical trials.
Proprietary biological datasets and foundation models enable novel target discovery and accurate drug-target binding predictions.
Generates novel molecular structures with desired properties, offering patent advantages.
Strategic partnerships with major pharmaceutical companies validate platform capabilities.

Limitations

Negative employee reviews citing terrible management, intimidation, and unfair treatment.
Poor work-life balance, low pay and benefits, and lack of job security and advancement according to employees.
Disastrous policy changes reportedly destroyed morale and drove people out.
Enterprise pricing is prohibitive for academic labs and small biotechs.
Long sales cycles and custom integration requirements extend time to value for new customers.
Black-box nature of deep learning models creates interpretability challenges for regulatory submissions.

Based on reviews from: Indeed.com, CompareThe.AI, Biology Digital, LaunchToolsAI, Reddit, G2 Learning Hub, G2.com, ACS Publications, MDPI, YouTube, The Pharma Letter, Drug Target Review, Wikipedia, Deep Pharma Intelligence, AWS

Last updated: 2026-08-10

Videos

News, demos, and interviews about Insilico Medicine.

Loading videos...

Videos load interactively. If none appear, search YouTube for Insilico Medicine →

View all on YouTube

Press & Coverage

EurekAlert!

Insilico Medicine Demonstrates AI-Powered Target Discovery for Rare Sinonasal Cancer in NPJ Precision Oncology

Insilico Medicine published a study in npj Precision Oncology demonstrating how AI and multi-omic analysis can identify therapeutic targets for rare sinonasal squamous cell carcinoma.

2026-08

Forbes

How Insilico Medicine Is Using AI To Reinvent Drug Discovery

Forbes highlights Insilico Medicine's use of generative AI to accelerate drug discovery, noting their success in bringing an AI-designed drug candidate to Phase 2 clinical trials in under 18 months.

2026-08

BioPharma APAC

Insilico Medicine's AI-Designed Cancer Drug Secures FDA Fast Track Status

Insilico Medicine announced that ISM6331, an AI-driven pan-TEAD inhibitor for advanced mesothelioma, received Fast Track Designation from the U.S. FDA, aiming to expedite its clinical development.

2026-07

Pharmaceutical Technology

Insilico Medicine and CMS Enter $177 Million AI-Powered Drug Discovery Collaboration

Insilico Medicine and China Medical System (CMS) have partnered in a collaboration potentially worth up to $177 million, focusing on AI-powered drug discovery for CNS diseases.

2026-07

Fierce Biotech

Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

Insilico Medicine and SK Biopharmaceuticals have formed an AI-enabled drug discovery partnership for neuroimmune disorders, with a potential value exceeding $2.5 billion.

2026-06

HLTH

Insilico Medicine Signs $2.75B AI Drug Discovery Partnership With Eli Lilly

Insilico Medicine entered a significant drug discovery agreement with Eli Lilly, potentially worth up to $2.75 billion, to leverage Insilico's AI platform for novel therapeutics across multiple areas.

2026-03

BioSpace

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Insilico Medicine and Liquid AI announced a partnership to create lightweight scientific foundation models for pharmaceutical research, enabling advanced AI capabilities without external cloud services.

2026-03

PR Newswire

Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation

Insilico Medicine closed a $110 million Series E financing round, led by Value Partners Group, to advance its innovative drug pipeline and AI platform developments.

2025-03

Frequently Asked Questions

What specific AI-driven products or therapies does Insilico Medicine offer that are relevant to clinical practice or healthcare administration?

Insilico Medicine primarily focuses on AI-driven drug discovery and development, with its core Pharma.AI platform encompassing PandaOmics for target identification and Chemistry42 for novel molecule generation. While they don't offer direct clinical tools for physicians, their lead drug candidate, rentosertib, for idiopathic pulmonary fibrosis, is currently in Phase II clinical trials, representing a potential future therapy derived from their AI platform.

How does Insilico Medicine ensure the regulatory compliance and data privacy of its AI platforms and drug candidates, especially given evolving healthcare AI regulations?

Insilico Medicine operates within the complex and evolving regulatory landscape of AI in drug development, with authorities like the FDA and EMA actively developing frameworks for safety, efficacy, and data integrity. Their lead drug candidate, rentosertib, has received Orphan Drug Designation from the FDA, indicating engagement with regulatory bodies.

What is Insilico Medicine's pricing model for its AI platforms or potential future therapies, particularly for healthcare systems or research institutions?

Insilico Medicine's business model primarily involves strategic partnerships and out-licensing deals with pharmaceutical companies, which typically include upfront payments, milestone payments, and royalties on future sales. Direct pricing models for healthcare systems or research institutions for their AI platforms are not publicly disclosed, suggesting a collaborative or enterprise-level engagement model.

What kind of support and integration assistance does Insilico Medicine provide for healthcare organizations looking to collaborate or utilize their AI-discovered assets?

Insilico Medicine engages in extensive collaborations with pharmaceutical companies, often integrating their Pharma.AI platforms with partners' development capabilities. They maintain a global presence with offices in key regions, which facilitates direct engagement and support for their partners.

What are Insilico Medicine's key partnerships within the pharmaceutical or healthcare industry, and how do these collaborations impact their product pipeline and market reach?

Insilico Medicine has established significant partnerships with major pharmaceutical companies, including a multi-billion dollar collaboration with Eli Lilly and an oncology-focused deal with Servier. They also partner with companies like Fosun Pharma, ASKA Pharmaceutical, and CMS, which expands their pipeline across various therapeutic areas and accelerates the development and commercialization of AI-discovered drugs.

What is the financial stability and long-term outlook of Insilico Medicine, especially as a clinical-stage AI-driven biotechnology company?

Insilico Medicine demonstrates strong financial stability, having raised over $1.05 billion across 12 funding rounds, including a recent Series E of $110 million. The company went public on the Hong Kong Stock Exchange in late 2025, further solidifying its financial standing and long-term outlook.

Investors

Who's funded Insilico Medicine.

Prosperity7 Ventures

Corporate VC AI T2

Dhahran, Saudi Arabia

$5M-$25M

Prosperity7 Ventures is the diversified growth fund of Aramco Ventures, headquartered in Dhahran, Saudi Arabia, with approximately $3 billion AUM deploying $5M-$25M…

AI/ML in Healthcare Digital Health

Related Companies

Suggest an Edit → | Report an issue